BR112013018762A2 - processo - Google Patents

processo

Info

Publication number
BR112013018762A2
BR112013018762A2 BR112013018762A BR112013018762A BR112013018762A2 BR 112013018762 A2 BR112013018762 A2 BR 112013018762A2 BR 112013018762 A BR112013018762 A BR 112013018762A BR 112013018762 A BR112013018762 A BR 112013018762A BR 112013018762 A2 BR112013018762 A2 BR 112013018762A2
Authority
BR
Brazil
Prior art keywords
iron
aqueous solution
hydroxypyrone
compound
precipitating
Prior art date
Application number
BR112013018762A
Other languages
English (en)
Inventor
Michael Arthur Stockham
Original Assignee
Iron Therapeutics Holdings Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43769665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013018762(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iron Therapeutics Holdings Ag filed Critical Iron Therapeutics Holdings Ag
Publication of BR112013018762A2 publication Critical patent/BR112013018762A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)

Abstract

processo a presente invenção fornece um processo de formação de um composto de hidroxipirona de ferro compreendendo a reação de uma hidroxipirona com um sal de ferro não-carboxilato em uma solução aquosa e a precipitação do composto de hidroxipirona de ferro a partir da solução aquosa com um ph superior a 7.
BR112013018762A 2011-01-27 2012-01-26 processo BR112013018762A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1101370.3A GB201101370D0 (en) 2011-01-27 2011-01-27 Process
PCT/GB2012/050160 WO2012101442A1 (en) 2011-01-27 2012-01-26 Process

Publications (1)

Publication Number Publication Date
BR112013018762A2 true BR112013018762A2 (pt) 2016-10-25

Family

ID=43769665

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013018762A BR112013018762A2 (pt) 2011-01-27 2012-01-26 processo

Country Status (14)

Country Link
US (2) US9096629B2 (pt)
EP (2) EP2668175B2 (pt)
JP (1) JP6055781B2 (pt)
KR (1) KR101925103B1 (pt)
CN (1) CN103443091B (pt)
AU (1) AU2012210337B2 (pt)
BR (1) BR112013018762A2 (pt)
CA (1) CA2824931C (pt)
ES (2) ES2627089T5 (pt)
GB (1) GB201101370D0 (pt)
RU (1) RU2621681C2 (pt)
SG (1) SG192153A1 (pt)
WO (1) WO2012101442A1 (pt)
ZA (1) ZA201305221B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015204192B2 (en) * 2014-01-06 2020-03-26 Shield TX (UK) Limited Dosage regimen of ferric trimaltol
GB201404390D0 (en) * 2014-03-12 2014-04-23 Iron Therapeutics Holdings Ag Composition
WO2015198304A1 (en) 2014-06-22 2015-12-30 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen
GB2531742B (en) * 2014-10-28 2016-10-05 Iron Therapeutics Holdings Ag Polymorphs of ferric maltol
US11517540B2 (en) 2015-01-09 2022-12-06 The Board Of Trustees Of The University Of Illinois Restoring physiology in iron-deficient organisms using small molecules
JP7033545B2 (ja) * 2016-03-31 2022-03-10 シールド ティーエックス （ユーケー） リミテッド 配位子修飾及び配位子コーティングされた水酸化第二鉄からマルトール第二鉄組成物を生成するための方法
EA201892194A1 (ru) 2016-03-31 2019-04-30 Юнайтед Киндом Рисёрч Энд Инновейшн Композиции комплекса трехвалентного железа с мальтолом для применения для лечения или предотвращения рака и опухолей
AU2017242906B2 (en) * 2016-03-31 2020-11-19 Shield TX (UK) Limited Methods for producing Ferric maltol compositions from Ferrous Hydroxides
JP7033546B2 (ja) * 2016-03-31 2022-03-10 シールド ティーエックス （ユーケー） リミテッド 元素鉄からマルトール第二鉄組成物を生成するための方法
IT202100018578A1 (it) 2021-07-14 2023-01-14 Indena Spa Dispersione amorfa di maltolo ferrico e relativo processo di preparazione
CN114113066B (zh) * 2021-12-27 2023-09-29 西北农林科技大学 麦芽酚铁过氧化物模拟酶在检测过氧化氢和总抗氧化能力中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54101445A (en) * 1978-01-27 1979-08-10 Sanei Kagaku Kogyo Kk Perfume maltol preparation
EP0107458B1 (en) 1982-10-22 1987-07-29 National Research Development Corporation Pharmaceutical compositions
USRE37534E1 (en) * 1982-10-22 2002-01-29 Btg International Limited Pharmaceutical compositions
GB8308055D0 (en) 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8410290D0 (en) 1984-04-19 1984-05-31 Callingham B A Pharmaceutical compositions
GB8410289D0 (en) * 1984-04-19 1984-05-31 Callingham B A Pharmaceutical compositions
ES2230564T3 (es) 1995-06-10 2005-05-01 Vitra Pharmaceuticals Ltd. Compuestos ferricos, composiciones, metodos de fabricacion de estos y sus utilizacioneds.
JP2000191516A (ja) * 1998-10-23 2000-07-11 Taisho Pharmaceut Co Ltd 経口固形組成物
DE10041893A1 (de) * 2000-08-25 2002-03-07 Truetzschler Gmbh & Co Kg Vorrichtung an einer Regulierstrecke zum direkten Ermitteln von Einstellwerten für den Reguliereinsatzpunkt
US20030190355A1 (en) * 2002-04-05 2003-10-09 Hermelin Marc S. Modified release minerals
GB0211500D0 (en) * 2002-05-18 2002-06-26 Vitra Pharmaceuticals Ltd Method of forming iron hydroxypyrone compounds
CN1408364A (zh) * 2002-09-20 2003-04-09 单玉华 一类补铁剂干混悬剂的处方组成
CA2550699A1 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc. Novel drug compositions and dosage forms of topiramate
BRPI0515847A (pt) * 2004-10-08 2008-08-12 Unilever Nv uso de um complexo de ferro, composição alimentìcia, gênero alimentìcio fortificado com ferro, composição de bebida, bebida fortificada com ferro, suplemento alimentar e composição farmacêutica
GB0808835D0 (en) 2008-05-15 2008-06-18 Vitra Pharmaceuticals Ltd Therapeutic compositions
US8996104B2 (en) * 2008-06-25 2015-03-31 Fe3 Medical, Inc. Patches and method for the transdermal delivery of a therapeutically effective amount of iron

Also Published As

Publication number Publication date
ZA201305221B (en) 2021-06-30
US20150320863A1 (en) 2015-11-12
RU2621681C2 (ru) 2017-06-07
US9096629B2 (en) 2015-08-04
ES2627089T5 (es) 2021-09-27
ES2627089T3 (es) 2017-07-26
JP2014503579A (ja) 2014-02-13
US20140088064A1 (en) 2014-03-27
CA2824931A1 (en) 2012-08-02
EP3192793B1 (en) 2022-03-16
EP3192793A1 (en) 2017-07-19
RU2013139544A (ru) 2015-03-10
SG192153A1 (en) 2013-08-30
AU2012210337A1 (en) 2013-03-21
AU2012210337B2 (en) 2014-07-17
GB201101370D0 (en) 2011-03-09
EP2668175B1 (en) 2017-03-08
EP2668175B2 (en) 2021-01-06
CA2824931C (en) 2019-08-06
CN103443091B (zh) 2017-05-10
EP2668175A1 (en) 2013-12-04
WO2012101442A1 (en) 2012-08-02
JP6055781B2 (ja) 2016-12-27
KR101925103B1 (ko) 2018-12-05
CN103443091A (zh) 2013-12-11
ES2918004T3 (es) 2022-07-13
KR20140022377A (ko) 2014-02-24

Similar Documents

Publication Publication Date Title
BR112013018762A2 (pt) processo
BR112013025732A2 (pt) composto de imidazo-oxazina ou sal do mesmo
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
WO2012116246A3 (en) Pesticidal compostions and processes related thereto
BR112013025760A2 (pt) reparo de menisco
MX346665B (es) Composiciones pesticidas y procedimientos relacionados con estas.
BR112015027055A2 (pt) compostos de bi-heteroarila e usos dos mesmos
PH12014502397A1 (en) Pesticidal compositions and processes related thereto
BR112015014555A2 (pt) composições pesticidas e processos relacionados a isso
MX361499B (es) Baricitinib deuterado.
BR112012017051A2 (pt) método para diminuir a imunogenicidade
BR112015007243A2 (pt) processo melhorado para fabricação de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluorometilpiridin-2-amina
MX2015001246A (es) Ibrutinib deuterado.
BR112014000837A2 (pt) aparelho para a produção de aços recozidos e processo para a produção dos ditos aços
BR112014010374A2 (pt) alimento para animais, uso de uma xilanase hiper-termofílica e hiper-termoestável, uso do alimento para animais e processo para produzir alimento para animais
BR112014029012A2 (pt) variantes de quimosina com propriedades melhoradas de coagulação do leite
BRPI0816398A2 (pt) Método, material e composição
BR112015013984A2 (pt) métodos para o tratamento de prurido
PH12015501457B1 (en) Aqueous carbonated beverage
BR122018074319B8 (pt) Método para preparar um composto de fórmula 14
MX2013008699A (es) Compuestos para reducir la produccion de beta-amiloide.
BR112014010061A2 (pt) processo para a preparação de n-alquil(met)acrila-midas
CA2851761C (en) Method of diagnosis, prognostic or treatment of neurodegenerative diseases
BRPI0908735A2 (pt) Método para produção de concentrados de minério de ferro.
UA115072C2 (uk) Похідні гідантоїну

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: SHIELD TX (UK) LIMITED (GB)

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL